Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


CTCF and BORIS in genome regulation and cancer.

Marshall AD, Bailey CG, Rasko JE.

Curr Opin Genet Dev. 2014 Feb;24:8-15. doi: 10.1016/j.gde.2013.10.011. Epub 2013 Dec 14. Review.


Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.

Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS.

Cancer Res. 2005 Sep 1;65(17):7763-74.


The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.

Klenova EM, Morse HC 3rd, Ohlsson R, Lobanenkov VV.

Semin Cancer Biol. 2002 Oct;12(5):399-414. Review.


Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.

Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H 3rd, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV.

Cancer Res. 2005 Sep 1;65(17):7751-62.


The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes.

Hore TA, Deakin JE, Marshall Graves JA.

PLoS Genet. 2008 Aug 29;4(8):e1000169. doi: 10.1371/journal.pgen.1000169.


Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.

Pugacheva EM, Rivero-Hinojosa S, Espinoza CA, Méndez-Catalá CF, Kang S, Suzuki T, Kosaka-Suzuki N, Robinson S, Nagarajan V, Ye Z, Boukaba A, Rasko JE, Strunnikov AV, Loukinov D, Ren B, Lobanenkov VV.

Genome Biol. 2015 Aug 14;16:161. doi: 10.1186/s13059-015-0736-8.


Widespread expression of BORIS/CTCFL in normal and cancer cells.

Jones TA, Ogunkolade BW, Szary J, Aarum J, Mumin MA, Patel S, Pieri CA, Sheer D.

PLoS One. 2011;6(7):e22399. doi: 10.1371/journal.pone.0022399. Epub 2011 Jul 19.


BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.

Hines WC, Bazarov AV, Mukhopadhyay R, Yaswen P.

PLoS One. 2010 Mar 17;5(3):e9738. doi: 10.1371/journal.pone.0009738.


The structural complexity of the human BORIS gene in gametogenesis and cancer.

Pugacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, Vostrov AA, Barsov E, Strunnikov AV, Morse HC 3rd, Loukinov D, Lobanenkov V.

PLoS One. 2010 Nov 8;5(11):e13872. doi: 10.1371/journal.pone.0013872.


The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.

Tiffen JC, Bailey CG, Marshall AD, Metierre C, Feng Y, Wang Q, Watson SL, Holst J, Rasko JE.

Int J Cancer. 2013 Oct 1;133(7):1603-13. doi: 10.1002/ijc.28184. Epub 2013 May 2.


CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer.

Fiorentino FP, Macaluso M, Miranda F, Montanari M, Russo A, Bagella L, Giordano A.

Mol Cancer Res. 2011 Feb;9(2):225-33. doi: 10.1158/1541-7786.MCR-10-0493. Erratum in: Mol Cancer Res. 2013 Oct;11(10):1292.


Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.

Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, Benhattar J, Lobanenkov V.

Nucleic Acids Res. 2007;35(21):7372-88. Epub 2007 Oct 25.


Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.

Hoivik EA, Kusonmano K, Halle MK, Berg A, Wik E, Werner HM, Petersen K, Oyan AM, Kalland KH, Krakstad C, Trovik J, Widschwendter M, Salvesen HB.

Oncotarget. 2014 Feb 28;5(4):1052-61.


BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.

Link PA, Zhang W, Odunsi K, Karpf AR.

Cancer Immun. 2013;13:6. Epub 2013 Jan 22.


Expression of the epigenetic factor BORIS (CTCFL) in the human genome.

de Necochea-Campion R, Ghochikyan A, Josephs SF, Zacharias S, Woods E, Karimi-Busheri F, Alexandrescu DT, Chen CS, Agadjanyan MG, Carrier E.

J Transl Med. 2011 Dec 14;9:213. doi: 10.1186/1479-5876-9-213. Review.


The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements.

Pugacheva EM, Teplyakov E, Wu Q, Li J, Chen C, Meng C, Liu J, Robinson S, Loukinov D, Boukaba A, Hutchins AP, Lobanenkov V, Strunnikov A.

Epigenetics Chromatin. 2016 Aug 31;9(1):35. doi: 10.1186/s13072-016-0084-2. eCollection 2016.


A cell cycle role for the epigenetic factor CTCF-L/BORIS.

Rosa-Garrido M, Ceballos L, Alonso-Lecue P, Abraira C, Delgado MD, Gandarillas A.

PLoS One. 2012;7(6):e39371. doi: 10.1371/journal.pone.0039371. Epub 2012 Jun 19.


Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.

Garikapati KR, Patel N, Makani VKK, Cilamkoti P, Bhadra U, Bhadra MP.

Biochem Biophys Res Commun. 2017 Feb 26;484(1):93-99. doi: 10.1016/j.bbrc.2017.01.066. Epub 2017 Jan 17.


The tumor suppressor role of CTCF.

Fiorentino FP, Giordano A.

J Cell Physiol. 2012 Feb;227(2):479-92. doi: 10.1002/jcp.22780. Review.


Discovering a binary CTCF code with a little help from BORIS.

Lobanenkov VV, Zentner GE.

Nucleus. 2018 Jan 1;9(1):33-41. doi: 10.1080/19491034.2017.1394536. Epub 2017 Dec 5. Review.

Supplemental Content

Support Center